Updated 08 November 2017

Scientists 'silence' aggressive brain cancer gene

Brain cancer, which kills about 13 000 Americans a year, may be stopped by using an experimental drug that could switch off the cancer gene.

An experimental drug has switched off a gene linked to an aggressive and incurable type of brain cancer and extended the lives of mice.

The brain cancer, glioblastoma multiforme, kills about 13 000 Americans a year and is the form of the disease that led to Senator Edward Kennedy's death in 2009.

The drug used in the study is based on nanotechnology and is small enough to cross the blood-brain barrier to get to brain tumours. It targets and turns off a specific cancer-causing gene in cells. Silencing the gene eliminates proteins that prevent cancer cells from dying.

Terrible disease

The mice received the drug via intravenous injection, and lived nearly 20% longer.  Their tumours were three to four times smaller, according to the study, which was published in the journal Science Translational Medicine.

"This is a beautiful marriage of a new technology with the genes of a terrible disease," said study senior co-author and nanomedicine expert Chad Mirkin, a professor of chemistry and medicine at Northwestern University.

Study senior co-author Alexander Stegh said: "Glioblastoma is a very challenging cancer and most chemo-therapeutic drugs fail in the clinic.

"The beauty of the gene we silenced in this study is that it plays many different roles in therapy resistance," said Stegh, an assistant professor in the neurology department at the Northwestern University Feinberg School of Medicine and an investigator at the Northwestern Brain Tumour Institute. 

Animal studies

"Taking the gene out of the picture should allow conventional therapies to be more effective."

The next step is to test the drug in clinical trials. Experts note that results achieved in animal studies often don't translate to humans.

About 16 000 new cases of glioblastoma multiforme are diagnosed in the United States each year. The average survival is 14 to 16 months.

More information

The American Brain Tumour Association has more about glioblastoma tumours.


Read Health24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Ask the Expert

Cancer expert

CANSA’s purpose is to lead the fight against cancer in South Africa. Its mission is to be the preferred non-profit organisation that enables research, educates the public and provides support to all people affected by cancer. Questions are answered by CANSA’s Head of Health Professor Michael Herbst. For more information, visit

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules